Lv61
1710 积分 2023-06-14 加入
Triple Agonist Therapy: A New Frontier in Treating Type 2 Diabetes and Obesity
20天前
已完结
Effectiveness, Safety and Pharmacokinetics of BGM0504, a Dual GLP-1/GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial
1个月前
已完结
The evolving landscape of obesity pharmacotherapy
2个月前
已完结
Repurposing glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of depression: A systematic review of preclinical, observational and clinical investigations
3个月前
已完结
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial
3个月前
已完结
Functional consequences of spatial, temporal and ligand bias of G protein-coupled receptors
4个月前
已完结
Molecular Design of Unimolecular Tetra-Receptor Agonists
4个月前
已完结
The GLP-1R as a model for understanding and exploiting biased agonism in next-generation medicines
4个月前
已完结
β−Arrestins: Structure, Function, Physiology, and Pharmacological Perspectives
4个月前
已完结
Molecular Determinants of Beta-Arrestin Binding to the Glucagon Receptor
4个月前
已完结
皖公网安备34019202002308
